This study examined whether serotonin reuptake inhibiting antidepressants (SRIs), including common SSRIs and SNRIs, may be linked to Visual Snow (VS) and Visual Snow Syndrome (VSS). Visual snow is a condition where people see constant “static” across their vision, often along with symptoms like afterimages, light sensitivity, and poor night vision. Although some earlier reports suggested a connection with antidepressants, strong evidence has been limited.
To investigate this, researchers analyzed patient-reported side effects from the global RxISK database. After screening the data, they identified 24 relevant cases from multiple countries, mostly involving young adults with an average age of 30. All patients reported visual snow, and about 42 percent had full visual snow syndrome with additional visual symptoms.
A key finding was when symptoms started and whether they improved over time:
- 58% developed symptoms while taking the drug
- 25% after reducing the dose
- 17% after stopping the drug
In most cases, the symptoms did not go away after stopping the medication. Specifically:
- 92% had ongoing symptoms
- Some cases lasted several years, up to more than 4 years
- A few patients reported symptoms worsened after stopping
The strength of the link between the drugs and symptoms was measured using a scoring system. The results suggested a meaningful association:
- 54% showed a strong link
- 38% showed a likely link
- The average score indicated an overall strong connection
These symptoms had a significant impact on daily life. Many patients reported problems with work and normal activities, changes in social relationships, and a need to seek medical care, often without clear answers or effective treatment.
Researchers suggest a few possible explanations. One is that these drugs may alter how the brain processes visual information, especially through serotonin-related systems. Another is that they may directly affect the eyes, including the retina or eye pressure. The pattern of symptoms, especially their persistence after stopping the drug, is similar to other long-lasting side effects linked to these medications.
In conclusion, the findings suggest that SRIs may trigger visual snow and related symptoms that often persist even after stopping the medication. As the use of these drugs continues to increase worldwide, awareness of this possible side effect is important, and more research is needed to understand why it happens and who is at risk.